Novartis charts new course in India, prioritizing innovation over generics

Novartis is moving away from its traditional generic drug business in India to concentrate on higher-value innovation activities, according to company executives Judith Love and Amitabh Dube. The pharmaceutical multinational plans to expand its presence in research and development, clinical trials, and strengthen India's regulatory environment—areas the company views as critical to its long-term growth strategy.

The strategic pivot reflects Novartis's assessment that India's innovation ecosystem is maturing and becoming increasingly attractive for advanced pharmaceutical work. By channeling investments into R&D and clinical research infrastructure, the company aims to position India as a hub for innovation rather than relying primarily on low-cost generic manufacturing.

The move underscores a broader trend among multinational pharmaceutical companies reassessing their India operations. As the country develops stronger intellectual property protections and regulatory frameworks aligned with global standards, firms are identifying opportunities to conduct sophisticated research and clinical work domestically rather than outsourcing such functions elsewhere.

Novartis's recalibration comes as India continues its transformation into a knowledge-intensive pharmaceutical hub. The company's focus on regulatory ecosystem improvements suggests it sees value in collaborating with Indian authorities to create conditions that support innovation-driven pharmaceutical development across the sector.